TY - JOUR
T1 - Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis
T2 - A pilot study
AU - Bruzzese, Eugenia
AU - Raia, Valeria
AU - Spagnuolo, Maria Immacolata
AU - Volpicelli, Monica
AU - De Marco, Giulio
AU - Maiuri, Luigi
AU - Guarino, Alfredo
N1 - Funding Information:
The authors thankfully acknowledge Jean Gilder for editorial assistance. The study was supported in part by a grant from Fondazione per la ricerca sulla fibrosi cistica. The specific contribution of each author was the following:
PY - 2007/6
Y1 - 2007/6
N2 - Background & aims: Probiotics reduce intestinal inflammation in children with cystic fibrosis (CF). We want to determine the effects of Lactobacillus GG (LGG) on pulmonary exacerbations in CF. Methods: A prospective, randomized, placebo-controlled, cross-over study was performed. Nineteen children received LGG for 6 months and then shifted to oral rehydration solution (ORS) for 6 months. In parallel nineteen received ORS and then shifted to LGG. Main outcome parameters were: incidence of pulmonary exacerbations and of hospital admissions, forced expiratory volume (FEV1), and modifications of body weight. Results: Patients treated with LGG showed a reduction of pulmonary exacerbations (Median 1 vs. 2, range 4 vs. 4, median difference 1, CI 95% 0.5-1.5; p=0.0035) and of hospital admissions (Median 0 vs. 1, range 3 vs. 2, median difference 1, CI95% 1.0-1.5; p=0.001) compared to patients treated with ORS. LGG resulted in a greater increase in FEV1 (3.6%±5.2 vs. 0.9%±5; p=0.02) and body weight (1.5 kg±1.8 vs. 0.7 kg±1.8; p=0.02). Conclusions: LGG reduces pulmonary exacerbations and hospital admissions in patients with CF. These suggest that probiotics may delay respiratory impairment and that a relationship exists between intestinal and pulmonary inflammation.
AB - Background & aims: Probiotics reduce intestinal inflammation in children with cystic fibrosis (CF). We want to determine the effects of Lactobacillus GG (LGG) on pulmonary exacerbations in CF. Methods: A prospective, randomized, placebo-controlled, cross-over study was performed. Nineteen children received LGG for 6 months and then shifted to oral rehydration solution (ORS) for 6 months. In parallel nineteen received ORS and then shifted to LGG. Main outcome parameters were: incidence of pulmonary exacerbations and of hospital admissions, forced expiratory volume (FEV1), and modifications of body weight. Results: Patients treated with LGG showed a reduction of pulmonary exacerbations (Median 1 vs. 2, range 4 vs. 4, median difference 1, CI 95% 0.5-1.5; p=0.0035) and of hospital admissions (Median 0 vs. 1, range 3 vs. 2, median difference 1, CI95% 1.0-1.5; p=0.001) compared to patients treated with ORS. LGG resulted in a greater increase in FEV1 (3.6%±5.2 vs. 0.9%±5; p=0.02) and body weight (1.5 kg±1.8 vs. 0.7 kg±1.8; p=0.02). Conclusions: LGG reduces pulmonary exacerbations and hospital admissions in patients with CF. These suggest that probiotics may delay respiratory impairment and that a relationship exists between intestinal and pulmonary inflammation.
KW - Cystic fibrosis
KW - Probiotics
KW - Pulmonary exacerbation
UR - http://www.scopus.com/inward/record.url?scp=34248588695&partnerID=8YFLogxK
U2 - 10.1016/j.clnu.2007.01.004
DO - 10.1016/j.clnu.2007.01.004
M3 - Article
SN - 0261-5614
VL - 26
SP - 322
EP - 328
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 3
ER -